Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharma focused on developing cystic fibrosis therapies, opened well above its initial public offering price on Friday in its first trading ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

The Boston area began 2025 with a record-high office vacancy rate of 17%. Yet there are at least seven notable office ...

HAPPY BIRTHDAY — to David Edelman, Ropes & Gray’s Abby Cable; former Gov. Charlie Baker senior adviser and the NCAA’s Tim ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...